Printo.it Website Review

The Paediatric Rheumatology INternational Trials Organisation (PRINTO) is a not for profit, non governmental, international research network Genoa. PRINTO initially included 14 European countries (about 90 countries, 650 centres worldwide with 1361 members today), with the goal to foster, facilitate and co-ordinate the development, conduct, an*lysis, and reporting of multi-centres, international clinical. PAEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION (PRINTO) The Paediatric Rheumatology INternational Trials Organisation (PRINTO) is a not for profit, non governmental, international research network founded by Alberto Martini and Nicolino Ruperto in 1996. PRINTO initially included 14 European countries (about 90 countries, 650 centres worldwide with 1361 members today), with the goal to foster, facilitate and co-ordinate the development, conduct, an*lysis, and Consensus proposal for Taxonomy of the Autoinflammatory Diseases (AIDs): ma.. Subcutaneous Abatacept in poly JIA Man*script published in Arthritis & Rheu.. Genoa will host the 2019 Meeting of the International Society of Systemic A.. Results of an international delphi survey for the definition of the variabl.. The PRINTO JAMAR Supplement published online in Rheumatology International Development & Initial Validation of the MAS Score man*script published in T.. Changes in Gene Expression in sJIA Patients on Canakinumab man*script publi.. PRINTO is partner of the conect4children (c4c) initiative, the collaborative network for European clinical trials for children, (c4c) a consortium that aims to enhance the competitiveness of Europe as a critical region for developing medicines for children. PRINTO is working with pharmaceutical companies as advisor for trials planning, centre selection, data collection, data an*lysis and The comparison of STep-up and step-down thera*eutic strategies in childhood ARthritiS trial (STARS) is a new interventional trial aiming to investigate whether an early aggressive thera*eutic intervention in children with JIA, based on the initial start of synthetic and